These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21704161)

  • 1. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
    Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
    Bartus RT; Herzog CD; Chu Y; Wilson A; Brown L; Siffert J; Johnson EM; Olanow CW; Mufson EJ; Kordower JH
    Mov Disord; 2011 Jan; 26(1):27-36. PubMed ID: 21322017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.
    Bartus RT; Kordower JH; Johnson EM; Brown L; Kruegel BR; Chu Y; Baumann TL; Lang AE; Olanow CW; Herzog CD
    Neurobiol Dis; 2015 Jun; 78():162-71. PubMed ID: 25841760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
    Kordower JH; Herzog CD; Dass B; Bakay RA; Stansell J; Gasmi M; Bartus RT
    Ann Neurol; 2006 Dec; 60(6):706-15. PubMed ID: 17192932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
    Gasmi M; Brandon EP; Herzog CD; Wilson A; Bishop KM; Hofer EK; Cunningham JJ; Printz MA; Kordower JH; Bartus RT
    Neurobiol Dis; 2007 Jul; 27(1):67-76. PubMed ID: 17532642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
    Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
    Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ; Snyder RO; Leff SE
    Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
    Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
    Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
    Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
    Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA; Su C
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.